The weak immunogenicity of
gliomas presents a barrier for effective
immunotherapy.
Na/H exchanger isoform 1 (NHE1) maintains alkaline intracellular pH (pHi) of
glioma cells and acidic microenvironment. In addition, NHE1 is expressed in
tumor-associated microglia and tumor-associated macrophages (TAMs) and involved in protumoral communications between
glioma and TAMs. Therefore, we hypothesize that NHE1 plays a role in developing
tumor resistance and immunosuppressive tumor microenvironment. In this study, we investigated the efficacy of pharmacological inhibition of NHE1 on combinatorial
therapies. Here we show that
temozolomide (TMZ) treatment stimulates NHE1
protein expression in two intracranial syngeneic mouse
glioma models (SB28, GL26). Pharmacological inhibition of NHE1 potentiated the cytotoxic effects of TMZ, leading to reduced
tumor growth and increased median survival of mice. Blockade of NHE1 stimulated proinflammatory activation of TAM and increased cytotoxic T cell infiltration into
tumors. Combining TMZ, anti-PD-1 antibody treatment with NHE1 blockade significantly prolonged the median survival in the mouse
glioma model. These results demonstrate that pharmacological inhibition of NHE1
protein presents a new strategy for potentiating TMZ-induced cytotoxicity and increasing
tumor immunogenicity for
immunotherapy to improve
glioma therapy.